Bavarian Nordic (OTCMKTS:BVNRY – Get Free Report) shares saw unusually-high trading volume on Tuesday. 3,696 shares changed hands during mid-day trading, an increase of 11% from the previous session’s volume of 3,328 shares. The stock last traded at $12.00 and had previously closed at $11.7750.
Bavarian Nordic Price Performance
The stock’s 50-day moving average price is $10.85 and its 200 day moving average price is $10.04. The firm has a market cap of $2.87 billion, a P/E ratio of 12.19 and a beta of 1.25.
Bavarian Nordic (OTCMKTS:BVNRY – Get Free Report) last announced its earnings results on Friday, August 21st. The company reported $0.46 EPS for the quarter. The business had revenue of $316.47 million during the quarter. Bavarian Nordic had a net margin of 24.36% and a return on equity of 11.97%.
About Bavarian Nordic
Bavarian Nordic A/S is a Denmark-based biotechnology company focused on developing, manufacturing and commercializing vaccines. The company serves government agencies, healthcare providers, travelers and other customers through a portfolio of products addressing infectious diseases and public-health preparedness.
Its best-known vaccine is MVA-BN, marketed as Jynneos in the United States and Imvanex in the European Union, for protection against smallpox and mpox. Bavarian Nordic also markets vaccines for rabies, including Rabipur and RabAvert, and for tick-borne encephalitis under the Encepur brand.
See Also
- Five stocks we like better than Bavarian Nordic
- Chip Stocks Are Sliding—Why Is Smart Money Buying?
- Adults Are Fueling a Toy Boom—These 4 Stocks Could Cash In
- Could Quantinuum’s Breakthrough Make Its Sell-Off a Bargain?
- Wired for Upside: Why Goldman Sachs Upgraded CoreWeave’s Battered Stock
Receive News & Ratings for Bavarian Nordic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic and related companies with MarketBeat.com's FREE daily email newsletter.
